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Context: In recent years changes in screening strategies for congenital hypothyroidism (CH) led to
an increased detection of mild forms of CH, associated with eutopic thyroid gland.
Objectives:We aimed to determine the clinical evolution of CHwith eutopic thyroid gland and to
find out prognostic factors at diagnosis and follow-up.
PatientsandMethods:Weretrospectivelyanalyzedagroupof84childrenwithCHandeutopic thyroid
gland treated at our institution. They all underwent clinical re-evaluation after the age of 3, based on
thyroid function testing after L-thyroxine therapywithdrawal, thyroid ultrasonography, and 123I scin-
tigraphy with perchlorate discharge test. Genetic analysis was performed in selected cases.
Results: At re-evaluation, 34.5% of patients showed permanent hypothyroidism and needed L-
thyroxine reintroduction, 27.4%hadpersistenthyperthyrotropinemia (TSH5–10mU/L), and38.1%
had transient hypothyroidism.Major risk factors for permanent CHwere prematurity, first-degree
familial history of goiter/nodules, thyroid hypoplasia at diagnosis, and high L-thyroxine require-
ments at follow-up. Iodine organification defects were found in 29.7% of patients, 30% of whom
harbored DUOX2 mutations. TSH receptor gene mutations were found in 8.7% of patients with
persistent thyroid dysfunction and negative perchlorate discharge test.
Conclusions: Only one-third of patients with CH and eutopic thyroid gland needed to continue
L-thyroxine therapy after re-evaluation. A frequent finding was the persistence of mild hyperthy-
rotropinemia. The evolution of CH remains difficult to predict, although different clinical features
might suggest different outcomes. Mutations in the genes commonly linked to mild forms of CH
were documented in a minority of cases. (J Clin Endocrinol Metab 98: 1395–1402, 2013)
Congenital hypothyroidism (CH) is one of themost rel-evant endocrine diseases of childhood, potentially
leading to permanent mental retardation if not diagnosed
and treated in the very early phases of life. In developed
countries neonatal screening programs allow a prompt
diagnosis and treatment ofCH, virtually abolishing severe
intellectual disability (1, 2).
In recent years several countries reported a significant
increase in CH incidence detected by newborn screening
programs, with an almost doubled number of detected
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cases compared to the usually reported incidence of
1:3000 to 1:4000. In particular, an increased incidence
was documented in Italy (1:2200 according to the Italian
National Registry of Infants with CH [3]; 1:1446 in Lom-
bardy region [4], 1:1749 in Greece [5], 1:1660 in Massa-
chusetts, USA [6]; 1:1415 in New York, USA [7], and
1:1077 in the United Kingdom [8]). The increasing inci-
dence is mostly explained by changes in screening pro-
grams, with the introduction of progressively lower cut-
offs to improve sensitivity (9, 10). These strategies led to
the detection of a higher number of mild forms of CH,
usually associated with a eutopic and normal-shaped thy-
roid gland (4). However, changes in some demographic
factors must be also considered. Indeed, migration trends
could have an influence because different ethnicities have
different incidence rates of CH, with higher susceptibility
in Asian Indian and Hispanic children (11). Another rel-
evant change in modern societies is the increasing number
of multiple pregnancies and preterm deliveries, mainly as
a result of assisted reproductive technologies, which are
considered risk factors for neonatal thyroid dysfunctions
(12–14).
In recent years, the increased incidence of mild and
potentially transitory formsof thyroiddysfunction started
a large debate on the clinical and economical conse-
quences of the new screening strategies adopted by most
countries (15–18), in particular, still unsolved issues re-
garding the increase in the recall of infants with false pos-
itive screening tests, and the benefits and costs related to
the early detection and treatment of mild forms of thyroid
dysfunction. At present, there are no clear data evidence
on the long-term clinical outcome ofmild hypothyroidism
or hyperthyrotropinemia, as far as both intellectual de-
velopment and metabolism are concerned. Moreover, al-
though novel molecular mechanisms of thyroid function
have been reported, the cause of these forms remains
largely unknown, and the genotype-phenotype correla-
tions for themost commonly involved genes, DUOX2and
TSH receptor, have been found to be more complex than
initially thought, probably due to the existence of genetic
and environmental modulators (19, 20).
Despite the presence of CH guidelines (21, 22), the
management of mild thyroid dysfunctions still greatly dif-
fers between single centers, especiallywith regard to initial
treatment and strategies for clinical re-evaluation to dis-
tinguish between transient and permanent forms.
In the present study, we aimed to determine the clinical
characteristics, the definitive diagnosis (ie, transient or
permanent CH), and the prevalence of the different forms
of CH in patients with a normally located thyroid gland.
We also analyzed the role played by the changes in neo-
natal screening programs (ie, the lowering of whole blood
TSH threshold to 10mU/L) on the clinical spectrumofCH
in this population.
The final goal is the definition of more appropriate and
personalized follow-up protocols for these children, and
consequently, better exploitation of clinical and econom-
ical resources.
Patients and Methods
All patients of our cohort were born between 1999 and 2005 in
Lombardy, a region with 9 642 406 inhabitants at census 2008,
characterized by a borderline mild-iodine deficiency, that has its
own newborn screening program, centralized in the Laboratory
for Neonatal Screening inMilan. The Screening Center adopts a
primary TSH method. The basal thyroid-stimulating hormone
(b-TSH) threshold level was lowered from 20 mU/L to 12 mU/L
in 1999, and then to 10 mU/L in 2002 (4).
In this period a total of 433 patients with positive CH screen-
ingwereput on L-thyroxine (L-T4) treatment, 289of themshow-
ing a normally located thyroid gland. One hundred sixty-six
patients with CH and eutopic thyroid glandwere referred to our
clinic (Pediatric Unit, San Raffaele Hospital, Milan, Italy). We
retrospectively analyzed a group of 84 consecutive patients who
underwent clinical re-evaluation after the age of 3, based on
thyroid function testing after L-T4 therapy withdrawal, thyroid
ultrasound, and radioiodine scanning (123I)withperchlorate dis-
charge test. Patients with Down syndrome or other major syn-
dromes were excluded.
CH diagnosis
Newborns with serumTSHpersistently higher than 10mU/L
andnormal or lo free thyroxine (fT4) valueswerediagnosedwith
CH. L-T4 therapy was introduced at initial doses of 8–14 g/kg
per day, according to the degree of hypothyroidism. Initial dose
was lower than 8 g/kg per day in 8 patients, who started treat-
ment after the second month of life, due to fluctuating TSH
values. Serum thyroglobulin (Tg), antibodies against TPO (TPO
auto-Ab), and TSH receptor (TSHR anto-Ab) were measured.
The presence of a eutopic normal-shaped thyroid gland was as-
certained with ultrasound, performed by the same radiologist
with experience in pediatric thyroid ultrasonography. The def-
inition of thyroid size was based on the measurement of the
anterior-posterior diameter of the gland, as compared to mea-
surements on a healthy population in our clinic. Four patients,
who did not perform ultrasound, underwent 99Tc scanning.
Clinical data on gestational age, delivery, maternal or neonatal
history of iodine exposure, congenital malformations, and fa-
milial thyroid disease were collected. All parents underwent thy-
roid function testing (ie, TSH and fT4), including the measure-
ment of maternal thyroid auto-antibodies.
All patients underwent periodical investigations at our center
to ascertain the correct L-T4 dosage and the regular psycho-
physical development.
Clinical re-evaluation protocol
Between the ages of 3 and 6 years, L-T4 therapy was with-
drawn for 4 weeks in all patients, and thyroid function was re-
tested (ie, TSH, fT4, free triiodothyronine, Tg, TPO, and TSHR
anto-Ab). Patients with TSH values 15 mU/L immediately re-
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sumed L-T4 therapy. Patients showing normal or slightly ele-
vated TSH elevation (ie, 5–15 mU/L) underwent repeated hor-
monal assessments at regular intervals to determine the TSH
trend.
On the basis of definitive TSH values at follow-up, after ther-
apy withdrawal, patients were divided into 3 groups:
• Permanent CH, if serum TSH steadily increased over 10
mU/L, requiring treatment reintroduction.
• Persistent hyperthyrotropinemia, defined as moderate serum
TSH elevation (5–10 mU/L) during follow-up; treatment was
restarted in selected cases with partial iodide organification
defect (PIOD) and/or familial history of goiter/thyroid
nodules.
• Transient CH, defined as normal thyroid function with nor-
mal serum TSH levels (5 mU/L) after therapy withdrawal
and during the subsequent follow-up of at least 1 year.
Thyroid size was reinvestigated by thyroid ultrasound, per-
formed by the same radiologist. Iodine organification defects
were detected by 123I scintigraphy with perchlorate discharge
test (23). In particular, a reduction 10% of the 123I uptake
levels at 2 hours after oral administration of sodium perchlorate
was considered positive for an iodide organification defect. Pa-
tients with iodide discharge of 10% to 90% were considered to
have a PIOD, whereas patients with iodide discharge greater
than 90% were considered to have a total iodide organification
defect (TIOD).
The genetic analyses were performed in most patients, ac-
cording to the perchlorate discharge test results (19). In 20 of 24
patients with PIOD, genetic analysis of DUOX2 and DUOXA2
geneswere done. The only patientwithTIODunderwent genetic
analysis of TPO. In 23 of 32 patients who were negative for
iodine organification defects but showed persistent thyroid dys-
function, TSH-receptor gene was analyzed.
Statistical analysis
Comparison between groups was performed using Kruskal-
Wallis test for nonparametric values. P  .05 was considered
statistically significant.
Results
A total of 84 consecutive patients (45 males, 39 females)
were analyzed in this study. A history of prematurity (n
19, 27–36weeks gestation) was present in 22.6%of cases
and 13% were dizygotic twins (n  11, only in 1 case
concordant for thyroid disease). Three childrenwere born
from in vitro fertilization (IVF) and 2 of them were twins.
Cesarean delivery occurred in 47.6% of patients, with
the prevalence decreasing to 40%if prematurity and twins
delivery are excluded.
Associated malformations were present in 14.3% of
patients (n 12), with a predominance of cardiac defects
(10cases, amongwhich4were severe and1wasassociated
with esophageal atresia); hypospadiawas found in2 cases.
At re-evaluation, 34.5% of patients (n  29) showed
permanent hypothyroidism; 27.4% of patients (n  23)
showed persistent hyperthyrotropinemia, and 38.1% of
patients (n  32) showed transient hypothyroidism.
Correlations between definitive diagnosis and the clin-
ical and instrumental features at diagnosis and re-evalu-
ation were investigated.
Analysis of clinical and biochemical features at
diagnosis (Table 1)
Differences in the rate of cesarean section, sex, neonatal
screening values, serum TSH, and fT4 at diagnosis were
not significant between the 3 groups of patients. Preterm
children showed a high rate of permanent CH (52.7%),
representing 34.5%of the cohortwith permanentCH.All
patients born after IVF had permanent CH.
Among laboratory parameters at diagnosis, we found
higher levels of Tg in patients with transient hypothyroid-
Table 1. Clinical and Biochemical Features at CH Diagnosis: Comparison Between Patients With Permanent CH,
Persistent Hyperthyrotropinemia, and Transient CH
Permanent CH
(n  29; 34.5%)
Persistent
Hyperthyrotropinemia
(n  23; 27.4%)
Transient CH
(n  32; 38.1%)
Sex: F/M 13/16 10/13 17/15
Preterms (37 gestational weeks) 10 (34.5%) 4 (17.4%) 5 (15.6%)
Caesarean section 15 (51.7%) 10 (43.5%) 15 (46.9%)
Twins 5 (17.2%) 2 (8.7%) 4 (12.5%)
Congenital malformations 4 (13.7%) 4 (17.4%) 4 (12.5%)
TSH screening (mU/L) 15 (5.2–135) 13.3 (10–54) 14.5 (10–85)
Serum TSH (mU/L) (n.v. 0.5–6.3) 22.6 (10–331) 58.6 (11.5–601) 42.5 (10.8–418)
Serum fT4 (ng/dL) (n.v. 1.5–2.4) 1.1 (0.1–1.7) 0.7 (0.1–1.8) 1 (0.2–1.9)
Thyroglobulin (ng/mL) (n.v. 10–250) 107 (1–1469)a 423 (18.7–2250) 423.5 (24–2029)a
TSHR auto-Ab 0 3 (9.4%)
TPO auto-Ab 0 1 1
First-degree familial thyroid disease/thyroid nodules 10 (34.5%)/4 6 (26.1%)/2 6 (18.7%)/1
Ultrasound scan (no. patients) 29 22 29
● Hyperplasic gland (anteroposterior diameter 9 mm) 5 (17.2%) 10 (45.4%) 12 (41.3%)
● Hypoplastic gland (anteroposterior diameter 5 mm) 4 (13.7%) 1 (4.5%) 0
Abbreviations: F, female; M, male; n.v., normal values. Laboratory values are expressed as median (range).
a Significant difference for serum thyroglobulin between patients with permanent and transient CH (ie, P  .05, Kruskal-Wallis test).
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ism compared to patients with permanent CH (P  .05).
The comparison of baseline Tg levels between patients
with positive andnegative perchlorate testwas instead not
significant (Tg median values: 517.6 vs 500.1 ng/mL).
The presence of familial thyroid disease in first-degree
relatives was more frequent in persistent thyroid dysfunc-
tions (34.5% of patients with permanent CH and 26% of
patients with persistent hyperthyrotropinemia), with a
high prevalence of thyroid nodules. Only 18.7% of pa-
tients with transient CH had first-degree relatives with
thyroid disease, mainly represented by autoimmune
thyroiditis.
At thyroid ultrasound the finding of a hypoplastic thy-
roid gland was correlated with permanent hypothyroid-
ism (no patients with hypoplastic gland harbored tran-
sient hypothyroidism); this data were also confirmed by
the selective analysis of term children, excluding the po-
tential confounding factor of prematurity. The common
finding of a hyperplasic thyroid glandwas equally present
in transient CH and in persistent hyperthyrotropinemia
(41.3% and 45.4%, respectively) and was less frequent in
patients with permanent CH (17.2%).
Analysis of clinical and biochemical features at
re-evaluation (Table 2)
Mean age at treatment withdrawal was 4 years in all
groups of patients. There was no evidence that different
ages could influence thyroid function at treatment
withdrawal.
No difference in development or growth was found
among the 3 groups of patients.
We found significant differences in themean L-T4 dose
before withdrawal among the 3 groups (P  .001). In
particular, all patients with permanent CH had an L-T4
requirement above 2 g/kg per day.
Four patients with permanent CH had extremely low
fT4 (ie,0.3 ng/dL) after treatment withdrawal (13.8%).
In addition, 7 patients showed fT4 values in the lower
normal range (0.7–0.9 ng/dL). All patients with persistent
hyperthyrotropinemia and transient CH had normal fT4
values.
Thyroid ultrasound scan findings were different ac-
cording to the different diagnoses, although a hypoplastic
gland was a frequent finding in all 3 groups, probably as
a consequence of L-T4 replacement therapy. In particular,
hyperplasic glands at re-evaluation were associated with
permanent CH: this was documented in 3 patients with
severe hypothyroidism, characterized by elevated serum
TSH (60–200 mU/L) and low fT4 (0.1–0.9 ng/dL) at di-
agnosis, L-T4 requirements above 3 g/kg per day during
follow-up, and marked TSH elevation at therapy with-
drawal (81.6–200 mU/L). One patient harbored a Tg de-
fect; 1 patient had a confirmed TPO gene mutation,
whereas the third patient showed an organification defect
without known mutations (perchlorate washout of 20%,
negative analysis for DUOX and DUOXA mutations).
The former 2 patients had a familial history of thyroid
nodules.
The perchlorate discharge test was positive for iodide
organificationdefects in29.7%ofpatients (n25): 1 case
of TIOD and 24 cases of PIOD. Among them, 40% of
cases showed permanent CH at re-evaluation; 36% had
persistent hyperthyrotropinemia, and 24% had transient
CH. We found no significant correlations between hor-
monal data and the presence of iodide organification de-
fect. The only patient with TIOD underwent genetic anal-
ysis of the TPO gene, which resulted positive for biallelic
mutations. In 20 of 24 patients with PIOD, genetic anal-
ysis of DUOX2 and DUOXA2 genes was performed,
showingmutations of DUOX2 in 6 cases (30%): 1 patient
showed permanent CH; 4 patients developed persistent
hyperthyrotropinemia, whereas 1 patient showed com-
plete normalization of thyroid function.
Table 2. Clinical and Biochemical Features at CH Re-evaluation: Comparison Between Patients With Permanent CH,
Persistent Hyperthyrotropinemia, and Transient CH
Permanent CH
(n  29; 34.5%)
Persistent
Hyperthyrotropinemia
(n  23; 27.4%)
Transient CH
(n  32; 38.1%)
L-Thyroxine dose (g/kg/d) 2.15 (1–3.7)a 1.64 (0.86–2.62)a 1.35 (0.4–2.55)
Serum TSH (mU/L) (n.v. 0.25–5) 10.83 (4.4–126.5) 6.95 (3.67–10.4) 3.7 (1.47–7.86)
Serum fT4 (ng/dL) (n.v. 0.7–1.7) 1.09 (0.2–1.38) 1.20 (0.95–1.61) 1.33 (0.93–1.83)
Ultrasound scan
● Hyperplasic gland (anteroposterior diameter 12 mm) 3 (10.3%) 0 0
● Hypoplastic gland (anteroposterior diameter 7 mm) 10 (34.4%) 9 (39.1%) 13 (40.6%)
Iodine organification defect 10 (34.4%) 10 (35.7%) 5 (18.5%)
Abbreviation: n.v., normal values. L-Thyroxine dose is expressed as median (range).
a Significant difference for L-thyroxine between patients with permanent and transient CH (ie, P  .001, Kruskal-Wallis test) and between patients
with permanent CH and persistent hyperthyrotropinemia (ie, P  .05).
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In 23of 32patientswith negative perchlorate discharge
test and persistent thyroid dysfunction, the TSH receptor
gene was analyzed. Mutations were found in 2 patients
(8.7%), both with hypoplastic thyroid gland at diagnosis
and permanent CH.
Comparison between patients with screening TSH
<20 mU/L and screening TSH >20 mU/L (Table 3)
b-TSH value at neonatal screening was 20 mU/L in
76.2% of patients (n  64). Therefore, all these cases
would have been missed before 1999, when the screening
cutoff in the Lombardy region was lower. Interestingly,
serum confirmatory values of these patients often showed
severe forms of CH: fT4 was low for age (1.5 ng/dL;
normal values, 1.5–2.4 ng/dL) in 79.7% of cases; serum
TSH increased to levels 50 mU/L in 37.5%, and 100
mU/L in 21.8% of cases. The definitive diagnosis at re-
evaluation in patients with lower screening TSH values
(20 mU/L) show the same distribution as patients with
screening TSH 20 mU/L.
Discussion
Congenital hypothyroidism has evolved into a condition
whose manifestations range from severe to mild (16). In-
ternational guidelines recommend towithdrawL-T4 ther-
apy after the age of 3 years in case of CH with eutopic
thyroid gland, to evaluate the persistence of the condition
(22). Currently, however, no specific indications exist on
how to perform diagnostic re-evaluation and the fol-
low-up of these patients, mainly due to the lack of large-
scale, long-term studies on milder forms of CH.
In our study we analyzed the clinical and biochemical
features and the outcome of 84 patients with CH and
eutopic thyroid gland, followed at a single center, who
systematically underwent re-evaluation after the age of 3
years. Remarkably, more than one-third of patients
(38.1%) showed a complete normalization of thyroid
function after treatment withdrawal, confirmed after at
least 1 year of follow-up. This prevalence of transient hy-
pothyroidism is similar to that reported by Gaudino et al
(24) and highlights the importance of diagnostic re-eval-
uation to avoid unnecessary treatment later in life. In
the remaining two-thirds of patients, however, a per-
sistence of thyroid dysfunction was demonstrated:
34.5% of cases showed permanent CH, requiring L-T4
therapy reintroduction, and 27.4% of cases showed
persistent hyperthyrotropinemia.
In our clinical experience it is crucial to monitor TSH
values closely in the first months after treatment with-
drawal, which occurred at a mean age of 4 years in the
present cohort. Indeed, slightly elevatedTSHvalues found
immediately after withdrawal can both normalize and in-
crease over time, as well as normal TSH values can in-
crease promptly or at severalmonths from treatmentwith-
drawal. We cannot exclude that a second attempt to
withdraw treatment at the end of pubertal development
could lead to new information on the progression of thy-
roid dysfunction.
It is interesting to observe that patients with screening
b-TSH values20mU/L showed the same distribution of
clinical outcomeafter therapywithdrawal as patientswith
higher screening values. The former cases represent more
than two-thirds of our cohort (76.2%of patients) but they
could be considered a “newly detected population,” as
theywouldhavebeenmissed inour regionbefore 1999.At
CH diagnosis, 79.7% of the patients with b-TSH 20
mU/L showed low levels of fT4 for age. At re-evaluation
34.3%of those children showedpermanentCH, requiring
L-T4 treatment, and 28% showed persistent hyperthyro-
tropinemia, needing periodical thyroid function retesting.
Thus, present data support the new screening strategies
that introduced lower screening TSH thresholds, leading
to an early detection of a large number of patients with
persistent thyroiddysfunction.Nevertheless, further long-
term studies are needed to establish the benefits of treat-
ment of milder cases of CH also considering that no data
Table 3. Comparison of Patients With Screening TSH 20 mU/L and Screening TSH 20 mU/L: Biochemical
Features at CH Diagnosis and Definitive Diagnosis at Re-evaluation
Screening TSH
(<20 mU/L; n  64; 76.2%)
Screening TSH
(>20 mU/L; n  20; 23.8%)
Preterms (37 gestational weeks) 14 (21.8%) 5 (25%)
Serum TSH, mU/L (n.v. 0.5–6.3) 29.8 (10–418) 78.7 (12–601)
Serum fT4 (ng/dL) (n.v. 1.5–2.4) 1.0 (0.2–1.9) 0.7 (0.1–1.7)
Thyroglobulin (ng/mL) (n.v. 10–250) 354 (7.2–2250) 122 (1–1380)
Definitive diagnosis
● Permanent CH 22 (34.3%) 7 (35%)
● Persistent hyperthyrotropinemia 18 (28%) 5 (25%)
● Transient CH 24 (37.5%) 8 (40%)
Abbreviation: n.v., normal values. Laboratory values are expressed as median (range).
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are available about the intellectual outcome of these pa-
tients (18).
The overview of our population discloses a remarkable
number of pretermchildren (22.6%) compared to the gen-
eral Italian population (6.75% in 2009 [25]), with a high
prevalence of permanent CH in this category of patients
(52.7%). Certainly, as reported in literature, thyroid dys-
functions in preterm newborns often rapidly improve
spontaneously, without need for hormonal treatment
(26). Nonetheless, our work suggests that preterm new-
borns presenting TSH values 10 mU/L, confirmed over
time, develop permanent CH more frequently as com-
pared to term newborns. This is in accordance with data
reported by Mengreli et al showing permanent thyroid
dysfunction in 83.3% of preterm newborns initially
treated for CH (5). The prevalence of twins in our series
(13%) was considerably higher than in the normal pop-
ulation (1.5% in Italy [25]). This is concordant with the
3-fold risk of CH in twins described in literature (12). All
patients born after IVF, in accordance with data reported
by Sakka et al, showed permanent CH (14).
Familial history for thyroid diseases was found to be
frequent in all 3 categories of patients: a deeper analysis
showed that maternal autoimmune disease, mainly with
antibodies against TSH receptor, was related to transient
hypothyroidism,whereas familial cases of goiter and nod-
ular disease were more frequently recorded in children
with permanent CH.
In addition, we looked for clinical or biochemical in-
dexes possibly predicting the persistence of hypothyroid-
ism by analyzing the features at diagnosis (Table 4). We
did not find significant differences in hormonal values be-
tween the 3 groups, with the exception of higher Tg levels
in patients with transient CH and persistent hyperthyro-
tropinemia, compared to permanent CH. This could be
explained by the fact that Tg usually rises in response to
transient interferences in thyroid hormone synthesis or in
the case of iodine organification defects. As recently re-
ported by different authors, DUOX2 mutations typically
cause transient CH or develop into mild hyperthyro-
tropinemia after the first years of life (27–29).
The ultrasonographic finding of a hypoplastic thyroid
gland at diagnosis was related to permanent CH. Thyroid
ultrasound at diagnosis is therefore an important diag-
nostic tool that can also hint to the patient’s prognosis. In
contrast, the finding of a hypoplastic gland at re-evalua-
tion is frequent and without clinical relevance. Thyroid
volume is probably influenced by replacement therapy,
most patients showing anormal or hypoplastic gland soon
after L-T4 withdrawal. On the other hand, the finding of
a hyperplasic gland at re-evaluation was invariably asso-
ciated with severe permanent hypothyroidism due to io-
dide organification defects. In this subgroup of patients,
the administration of higher L-T4 dosage should be con-
sidered, to keep TSH levels below 2 mU/L, preventing or
at least limiting, thyroid enlargement.
Another feature associatedwith the permanence of CH
was found to be the L-T4 dose at the time of withdrawal,
as already reported by other authors (30). In our study, all
patients with permanent hypothyroidism had L-T4 re-
quirements higher than 2 g/kg per day.
An important issue raised by our analysis regards the
utility of perchlorate discharge test at re-evaluation. In our
population, it helped to detect an organification defect in
approximately 30% of patients, most them (80%) show-
ing persistent thyroid dysfunctions. Because those cases
showed a wide clinical variability, probably due to the
different genetic background, we believe that it would be
difficult to select a candidate category for the test. Thus,
our indication would be to perform the perchlorate dis-
charge test only in specialized centerswith themain aim to
target the genetic analyses.
Genetic analysis forDUOXandDUOXA,performed in
20 patients with PIOD, showed a mutation of DUOX in
30%of cases. Further studies investigating the correlation
between genotype and phenotype are needed to select pa-
tients better for DUOX2 analysis. Moreover, the absence
of DUOX2 mutations in a significant number of our pa-
tients with PIOD suggests that other still unknown mo-
lecularmechanismsare responsible formostof these cases.
Another critical point is related to the follow-up of pa-
tients with an iodide organification defect and a normal
thyroid function (20%ofour series): should these children
bemonitored for the potential risk of goiter in adult age or
should they be considered as transient hypothyroid? Also,
in this case, a long-term follow-up could clarify the risk
and help optimize health resources.
Patientswith apersistent thyroiddysfunctionandwith-
out iodide organification defects were submitted to TSHR
gene analysis. We found a mutation in 2 patients (8.7%),
both with hypoplastic thyroid gland at diagnosis and per-
manentCHat re-evaluation.TheprevalenceofTSHRmu-
tation in our population is similar to that recently reported
byNarumi et al (31) and Calebiro et al (32). Interestingly,
in most cases of permanent CH, we could not identify the
cause of thyroid dysfunction. In fact, 65.6% of patients
with negative perchlorate test were negative for a TSHR
Table 4. Risk Factors for Permanent CH
● Prematurity
● First-degree relatives with history of goiter/nodules
● Thyroid hypoplasia at diagnosis
(anteroposterior diameter 5 mm)
● High L-thyroxine requirements at re-evaluation (2 g/kg/d)
● Thyroid hyperplasia at re-evaluation
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gene mutation, indicating that further studies are needed
to elucidate mechanisms of thyroid dysfunction in this
large cohort of patients.
In conclusion, CH with eutopic thyroid gland is an ex-
tremely complex condition, still lacking consensus regard-
ing its diagnosis and treatment.Our study investigated the
phenotype of a large cohort of patients, highlighting dif-
ferent aspects that are still amatter of debate.The frequent
persistence of thyroid dysfunctions at re-evaluation also in
patients with initial low screening TSH values underlines
the importance of redefining screening strategies, with
special attention toward high-risk categories like preterm
newborns. Similarly, a diagnostic re-evaluation after 2 to
3 years of age is needed to identify transient forms of CH.
We showed that the examination of thyroid volume at
diagnosis and at re-evaluation, aswell as the L-T4 require-
ments at follow-up and the familial history for thyroid
disease, can represent useful prognostic data. Genetic de-
fects are certainly responsible for a high percentage of
patients with a persistent thyroid dysfunction, even
though our knowledge is still limited in this field. Indeed,
mutations in the currently known genes linked to mild
forms of CH (DUOX and TSHR) explain only a minority
of cases. It is likely that CH with eutopic thyroid gland
could not be a monogenic disease, and that epigenetic
mechanisms and environmental factors could be involved
in disease expression. For example, the mild iodine defi-
ciency documented in the Lombardy region may contrib-
ute to the elevated incidence of CH with in situ thyroid
gland (1:1446) detected in this region. It could be specu-
lated that a more efficient iodine prophylaxis, especially
during pregnancy, would reduce the number of patients
with transient CH and persistent mild thyroid dysfunc-
tions. Further studies on long-term follow-up and geno-
type-phenotype correlations are needed to improve our
understanding of congenital thyroid dysfunctions and to
clarify the best clinical management for these patients.
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